INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Key Takeaways Inovio stock rises 20.6% after the FDA allows a rolling BLA for INO-3107 in RRP.The company aims to seek priority review for INO-3107, cutting FDA review time to six months.INO-3107 has breakthrough therapy and orphan drug designations for RRP.Shares of Inovio Pharmaceuticals (INO) jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for INO-3107 in adult patients with recurrent respiratory papi ...